CN113766917A - 用于治疗头颈癌的喹啉衍生物 - Google Patents

用于治疗头颈癌的喹啉衍生物 Download PDF

Info

Publication number
CN113766917A
CN113766917A CN202080031678.XA CN202080031678A CN113766917A CN 113766917 A CN113766917 A CN 113766917A CN 202080031678 A CN202080031678 A CN 202080031678A CN 113766917 A CN113766917 A CN 113766917A
Authority
CN
China
Prior art keywords
cancer
head
carcinoma
neck
sal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080031678.XA
Other languages
English (en)
Inventor
王善春
张彬
王伟锋
徐萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113766917A publication Critical patent/CN113766917A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Abstract

化合物1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺在制备用于治疗头颈癌的药物中的用途，以及其联合第二治疗药物的药物组合物在制备用于治疗头颈癌的药物中的用途，所述头颈癌可以是鼻咽癌。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202080031678.XA 2019-05-23 2020-05-25 用于治疗头颈癌的喹啉衍生物 Pending CN113766917A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019104335647 2019-05-23
CN201910433564 2019-05-23
PCT/CN2020/092125 WO2020233723A1 (zh) 2019-05-23 2020-05-25 用于治疗头颈癌的喹啉衍生物

Publications (1)

Publication Number Publication Date
CN113766917A true CN113766917A (zh) 2021-12-07

Family

ID=73458380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080031678.XA Pending CN113766917A (zh) 2019-05-23 2020-05-25 用于治疗头颈癌的喹啉衍生物

Country Status (6)

Country Link
US (1) US20220211694A1 (zh)
EP (1) EP3973963A4 (zh)
CN (1) CN113766917A (zh)
AU (1) AU2020278733A1 (zh)
CA (1) CA3141174A1 (zh)
WO (1) WO2020233723A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160700A1 (en) * 2018-07-18 2022-05-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Therapeutic combination of quinoline derivative and antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105213394A (zh) * 2014-06-06 2016-01-06 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
CN107771078A (zh) * 2015-05-04 2018-03-06 爱德程医药有限公司 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法
CN107970241A (zh) * 2018-01-22 2018-05-01 上海市第人民医院 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤的应用
CN111757736A (zh) * 2018-03-14 2020-10-09 正大天晴药业集团股份有限公司 治疗鼻咽癌的喹啉衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105213394A (zh) * 2014-06-06 2016-01-06 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
CN107771078A (zh) * 2015-05-04 2018-03-06 爱德程医药有限公司 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法
CN107970241A (zh) * 2018-01-22 2018-05-01 上海市第人民医院 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤的应用
CN111757736A (zh) * 2018-03-14 2020-10-09 正大天晴药业集团股份有限公司 治疗鼻咽癌的喹啉衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV: "A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas", 《HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT03591666?V_1=VIEW#STUDYPAGETOP》 *
CLINICALTRIALS.GOV: "Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma", 《HTTPSCLINICALTRIALS.GOVCT2HISTORYNCT03639467V_2=VIEW#STUDYPAGETOP》 *

Also Published As

Publication number Publication date
WO2020233723A1 (zh) 2020-11-26
AU2020278733A1 (en) 2022-01-06
EP3973963A1 (en) 2022-03-30
US20220211694A1 (en) 2022-07-07
CA3141174A1 (en) 2020-11-26
EP3973963A4 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
CN113347996B (zh) 治疗肿瘤的联用药物组合物
JP2021522298A (ja) 癌治療のためのＰＤ−１／ＰＤ−Ｌ１、ＴＧＦβおよびＤＮＡ−ＰＫの同時阻害
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
CN113905761A (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN113811298B (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
WO2023035223A1 (zh) 药物组合物及其用途
WO2023093663A1 (en) Pharmaceutical composition and use thereof
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
CN112121048A (zh) 用于联合治疗食管癌的喹啉类化合物
TWI812820B (zh) 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法
CN113766917A (zh) 用于治疗头颈癌的喹啉衍生物
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN113286614A (zh) 用于治疗癌症的pd-1拮抗剂、atr抑制剂和铂化物质的组合
WO2019096233A1 (zh) 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途
CN112043832A (zh) 用于联合治疗胃癌的喹啉类化合物
TW202345900A (zh) 抗tim-3抗體與去甲基化藥物的藥物組合
CN115779095A (zh) 治疗结直肠癌的喹啉衍生物与pd-1单抗的药物组合
CN116209443A (zh) 治疗小细胞肺癌的药物组合
CN113750096A (zh) 用于治疗外周t细胞淋巴瘤的喹啉衍生物
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物
EP4056200A1 (en) Drug combination of quinoline derivative and pd-1 monoclonal antibody
CN117642181A (zh) 用于治疗食管癌的药物组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination